Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - raztopina za kožni vbodni test - alergijski testi

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - raztopina za kožni vbodni test - alergijski testi

Den europeiske union - slovensk - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - zdravila za obstruktivne pljučne bolezni, - alergijske asthmaxolair je navedeno pri odraslih, mladostnikih in otrocih (6 do.

Den europeiske union - slovensk - EMA (European Medicines Agency)

ge healthcare as - flutemetamol (18f) - radionuclide imaging; alzheimer disease - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. vizamyl je radiofarmacevtski izdelek, zdravilo, ki je navedena za positron emission tomografija (pet) slikanje β amyloid neuritic plošča gostote v možgane odraslih bolnikih z kognitivne motnje, ki so bili ovrednoteni za alzheimerjevo bolezen (ad) in drugih vzrokov kognitivne motnje. zdravilo vismyl je treba uporabiti v povezavi s klinično oceno. negativno skeniranja, kaže, redke ali ne, plošče, ki ni v skladu z diagnozo oglasov.

Den europeiske union - slovensk - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - zdravila za obstruktivne pljučne bolezni, - fasenra je indicirano kot dodatek na vzdrževanje zdravljenje pri odraslih bolnikih s hudo eozinofilno astmo neustrezno nadzorovano kljub visoki odmerki vdihavajo kortikosteroide plus dolgo delujoči beta agonistov.

Den europeiske union - slovensk - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - zdravila za obstruktivne pljučne bolezni, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Den europeiske union - slovensk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - sredstva za dermatitis, razen kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Den europeiske union - slovensk - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopic - drugi dermatološki preparati - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Den europeiske union - slovensk - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - drugi dermatološki preparati - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Den europeiske union - slovensk - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - zdravila za obstruktivne pljučne bolezni, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.